ANAPTYSBIO, INC
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
ANAB$48.38+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Gain (Loss) · Deficit · Equity | |||||||||
| Balance, January 1, 2023 | 28,513 | $29 | $717,797 | $(5,246) | $(450,477) | $262,103 | |||
| Issuance of common stock from exercises of options and employee stock purchase plan | 139 | — | 2,421 | — | — | 2,421 | |||
| Issuance of common stock upon vesting of restricted stock units | 69 | — | — | — | |||||
| Repurchases and retirements of common stock | (2,124) | (2) | (50,454) | — | — | (50,456) | |||
| Stock-based compensation | — | — | 33,205 | — | — | 33,205 | |||
| Comprehensive income | — | — | — | 4,449 | — | 4,449 | |||
| Net loss | — | — | — | — | (163,619) | (163,619) | |||
| Balance, December 31, 2023 | 26,597 | 27 | 702,969 | (797) | (614,096) | 88,103 | |||
| Issuance of common stock from exercises of options and employee stock purchase plan | 364 | — | 6,473 | — | — | 6,473 | |||
| Issuance of common stock upon vesting of restricted stock units | 1,108 | — | — | — | — | — | |||
| Net share settlement of restricted stock units | (347) | — | (7,504) | — | — | (7,504) | |||
| Issuance of common stock, net of $6,516 of transaction costs | 2,751 | 3 | 93,874 | — | — | 93,877 | |||
| Stock-based compensation | — | — | 34,048 | — | — | 34,048 | |||
| Comprehensive income | — | — | — | 1,102 | — | 1,102 | |||
| Net loss | — | — | — | — | (145,231) | (145,231) | |||
| Balance, December 31, 2024 | 30,473 | 30 | 829,860 | 305 | (759,327) | 70,868 | |||
| Issuance of common stock from exercises of options and employee stock purchase plan | 732 | 1 | 14,290 | — | — | 14,291 | |||
| Issuance of common stock upon vesting of restricted stock units | 356 | — | — | — | — | — | |||
| Net share settlement of restricted stock units | (98) | — | (1,451) | — | (1,451) | ||||
| Repurchases and retirements of common stock | (3,444) | (3) | (69,006) | — | — | (69,009) | |||
| Stock-based compensation | — | — | 36,072 | — | — | 36,072 | |||
| Comprehensive loss | — | — | — | (329) | — | (329) | |||
| Net loss | — | — | — | — | (13,232) | (13,232) | |||
| Balance, December 31, 2025 | 28,019 | $28 | $809,765 | $(24) | $(772,559) | $37,210 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.